A Janus kinase (JAK) inhibitor outperformed tumor necrosis factor (TNF) blockers for substantially reducing rheumatoid arthritis (RA) symptoms in patients for whom conventional anti-rheumatic drugs ...

WASHINGTON (Reuters) - U.S. health regulators have received more reports of rare blood cancer in young patients taking a class of anti-inflammatory drugs used to treat digestive disorders. The drugs, ...

Expert Rev Clin Immunol. 2010;6(1):9-19. In a large study with a total of 165 consecutive patients who received 479 infliximab infusions, [111] the overall incidence of infusion reactions was ...

Tumor necrosis factor inhibitors were not linked to additional weight gain in patients with psoriatic arthritis when age-related changes were considered.

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Kids with polyarticular-course juvenile idiopathic arthritis ...

BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNFA” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune ...

The Phase 1 clinical trial is a randomized, double-blind, placebo-controlled study evaluating single and multiple ascending doses of FT2109 in healthy adult volunteers. The trial will assess the ...

Infants exposed to TNF inhibitors in utero or through breast milk show no increased risk for severe infections or impaired ...

CHICAGO -- Hitting rheumatoid arthritis (RA) early and hard, with targeted therapies as first-line treatment, appears to reduce the likelihood that it will reach the dreaded "difficult-to-treat" stage ...

ATLANTA — According to new research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, continuing tumor necrosis factor inhibitors during pregnancy is not associated ...

The US Food and Drug Administration (FDA) has approved AbbVie’s supplemental new drug application, updating the indication statement for Rinvoq (upadacitinib) to treat inflammatory bowel disease. This ...

This medication, which is already used to treat ulcerative colitis and several inflammatory skin conditions, was recently approved by the FDA for patients with Crohn’s disease. For the first time, ...